Each week we bring you information about drugs, techniques, studies and education for your patients and we often find that there are certain things we could learn more about. We had our staff do a survey of recent information requests and found that there were a lot of you who …

The Mobile Application for Diabetes from Vree gives your patients a full suite of useful tools and provides Interactive Diabetes Education to supplement the advice you give patients, with extensive learning modules that patients can explore at their own pace. Follow this link to find out more and view a …

In this Special Edition on DPP-IV Inhibitors, we present a set of our Homerun Slides focused on The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes….

The dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical practice they are associated with significant reductions in HbA1c, no …

We often diagnose a patient with diabetes, give them a meter and a prescription and send them on their way. Some of us refer for education or even have an educator in our office but our patients fail no matter what we try. We have learned that there is a …

Foreword to the Second Edition       It is difficult to conceive of a disease more likely to cause psychological problems than diabetes.

In this week’s Homerun Slides, we cover DPP-IV inhibitors including a comparison of effects with GLP-1 receptor agonists….

How many of you can say you practice what you preach when it comes to food and exercise? How about your office staff, can you say that most of them exemplify the ideals that you promote to patients? Do you think that we have accepted unhealthy food choices, lack of …

A new study found that the incretin-related medications will see the strongest growth among type 2 diabetes drugs over the next nine years.…

FDA Approves New Use for BYETTA® (exenatide) BYETTA is now approved as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione (TZD), in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone.  See …